Bloodstream Infections: Are Seven Antibiotic Days

Why does antibiotic duration matter after COVID-19?

The CDC's account of COVID-19 and antimicrobial resistance describes how hospital pressures, disrupted infection prevention and antibiotic use undermined earlier progress. Almost 80% of patients hospitalized with COVID-19 received an antibiotic between March and October 2020, although antibiotics cannot treat the virus itself. Some patients needed treatment for bacterial infections, but the figure illustrates how widely antibiotics were used during the pandemic. These are historical findings, not newly collected October 2026 data. [CDC pandemic assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

Treatment duration is one practical opportunity to reduce unnecessary exposure. Antibiotics can cause diarrhea, allergic reactions and other adverse effects, and their use can contribute to resistance. Establishing the shortest effective course therefore matters even when the initial prescription is appropriate. The clinical challenge is to preserve recovery while avoiding additional doses that offer no demonstrated benefit. [CDC antibiotic guidance](https://www.cdc.gov/antibiotic-use/about/index.html).

What did the BALANCE antibiotic trial find?

BALANCE tested treatment duration across 74 hospitals in seven countries. Its findings were first published online in November 2024, providing evidence relevant to today's resistance concerns rather than a new drug announcement. The study asked whether a shorter course could preserve outcomes in hospitalized patients with bloodstream infections, a serious condition requiring effective antibiotic treatment. [Sunnybrook trial announcement](https://sunnybrook.ca/media/item.asp?c=2&f=results-from-balance-randomized-clinical-trial&i=3785&page=33939).

Death within 90 days occurred in 14.5% of patients assigned seven days and 16.1% assigned fourteen days. The shorter course met the prespecified noninferiority margin of four percentage points. That supports the shorter strategy within the study's boundaries; it does not establish that seven days improves survival. Treating teams selected the antibiotic, dose and administration route, so the trial evaluated duration across clinical practice. [BALANCE primary publication](https://www.nejm.org/doi/10.1056/NEJMoa2404991).

Who should avoid assuming seven days is enough?

BALANCE excluded bloodstream infections caused by Staphylococcus aureus, severe immunosuppression and infection sites requiring prolonged treatment. Its result therefore cannot justify a universal seven-day prescription. Clinicians need to consider the organism and underlying infection before applying the finding. [BALANCE eligibility and findings](https://www.nejm.org/doi/10.1056/NEJMoa2404991).

For patients, the practical step is to ask the treating team why a particular duration was chosen and whether the prescription has a clear stop date. Take antibiotics exactly as currently prescribed; feeling better alone is not a reason to change the course independently. Report side effects and seek clarification if discharge instructions conflict with earlier advice. Shorter treatment should follow an appropriate clinical decision, with instructions that the patient can follow confidently. [CDC patient guidance](https://www.cdc.gov/antibiotic-use/about/index.html).